ArticleJournal of gastroenterology and hepatology2026
The Diagnostic Accuracy of Fecal Calprotectin for Colonoscopic Abnormalities in Patients With Chronic Diarrhea.
Article in Journal of gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
Abstract
objectiveTo evaluate the diagnostic accuracy of the colloidal gold immunochromatographic assay-based fecal calprotectin (CGICA-FC) for detecting colonoscopic abnormalities in patients with chronic diarrhea.
methodsWe conducted a prospective diagnostic study across 15 centers in China. All patients with chronic diarrhea underwent colonoscopy. We quantitatively measured FC concentrations before bowel preparation and assessed diagnostic performance using ROC curve analysis.
resultsA total of 556 patients with chronic diarrhea and 152 nondiarrhea controls were enrolled. FC levels were significantly higher in patients with Crohn's disease, followed by ulcerative colitis and other inflammation, compared to those with high-risk adenomas, minor benign findings, normal mucosa, or nondiarrhea controls. For screening colonoscopic abnormalities from nonsignificant findings (normal mucosa & minor benign findings), the optimal cutoff was 93.8 μg/g (AUC = 0.830). FC demonstrated higher discriminatory power for colorectal inflammation (including IBD and other inflammation) with a cutoff of 118.4 μg/g (AUC = 0.896) and was most accurate for identifying IBD specifically (cutoff 157.0 μg/g, AUC = 0.929). However, its accuracy for detecting high-risk adenomas was limited (AUC = 0.587). FC showed high negative predictive value (NPV = 0.898-0.973) based on the prescreening patients with a low prior probability of abnormalities. Multivariate analysis identified colorectal inflammation and alcohol consumption as independent positive correlates with FC levels, while BMI showed a negative association.
conclusionThe CGICA-FC test is an accurate noninvasive tool for triaging patients with chronic diarrhea, with high diagnostic accuracy for identifying colorectal inflammation. Owing to its high NPV, it holds promise for reducing unnecessary colonoscopies in prescreening patients. CHINESE CLINICAL TRIAL REGISTRY: ChiCTR2300070117.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.